Endonovo Therapeutics Stock Performance
| ENDV Stock | USD 0.0001 0.00 0.00% |
Endonovo Therapeutics holds a performance score of 6 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.48, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Endonovo Therapeutics are expected to decrease at a much lower rate. During the bear market, Endonovo Therapeutics is likely to outperform the market. Use Endonovo Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to analyze future returns on Endonovo Therapeutics.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Endonovo Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Endonovo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Endonovo |
Endonovo Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.01 in Endonovo Therapeutics on October 6, 2025 and sell it today you would earn a total of 0.00 from holding Endonovo Therapeutics or generate 0.0% return on investment over 90 days. Endonovo Therapeutics is currently generating 1.5873% in daily expected returns and assumes 20.0166% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Endonovo, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Endonovo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Endonovo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Endonovo Therapeutics, and traders can use it to determine the average amount a Endonovo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0793
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ENDV | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Endonovo Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Endonovo Therapeutics by adding it to a well-diversified portfolio.
Endonovo Therapeutics Fundamentals Growth
Endonovo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Endonovo Therapeutics, and Endonovo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Endonovo Pink Sheet performance.
| Return On Asset | -1.1 | |||
| Operating Margin | (222.06) % | |||
| Current Valuation | 9.74 M | |||
| Shares Outstanding | 194.33 M | |||
| Price To Earning | (1.04) X | |||
| Price To Sales | 202.42 X | |||
| Revenue | 73.11 K | |||
| EBITDA | (1.51 M) | |||
| Cash And Equivalents | 59.98 K | |||
| Total Debt | 7.36 M | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (986.58 K) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 2.01 M | |||
| Retained Earnings | (17.63 M) | |||
| Current Asset | 245 K | |||
| Current Liabilities | 8.29 M | |||
About Endonovo Therapeutics Performance
Evaluating Endonovo Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Endonovo Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Endonovo Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California. Endonovo Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Endonovo Therapeutics performance evaluation
Checking the ongoing alerts about Endonovo Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Endonovo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Endonovo Therapeutics is way too risky over 90 days horizon | |
| Endonovo Therapeutics has some characteristics of a very speculative penny stock | |
| Endonovo Therapeutics appears to be risky and price may revert if volatility continues | |
| Endonovo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 73.11 K. Net Loss for the year was (3.1 M) with profit before overhead, payroll, taxes, and interest of 58.12 K. | |
| Endonovo Therapeutics currently holds about 59.98 K in cash with (986.58 K) of positive cash flow from operations. | |
| Roughly 25.0% of the company shares are held by company insiders |
- Analyzing Endonovo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Endonovo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Endonovo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Endonovo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Endonovo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Endonovo Therapeutics' pink sheet. These opinions can provide insight into Endonovo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Endonovo Pink Sheet Analysis
When running Endonovo Therapeutics' price analysis, check to measure Endonovo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endonovo Therapeutics is operating at the current time. Most of Endonovo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Endonovo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endonovo Therapeutics' price. Additionally, you may evaluate how the addition of Endonovo Therapeutics to your portfolios can decrease your overall portfolio volatility.